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The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the
treatment of advanced Parkinson’s disease (PD). Of 22 enrolled patients 21 completed the study. A rater blinded to treatment
evaluated Unified Parkinson’s Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment
Scale, and a structured questionnaire on ropinirole side effects. Besides, the patients self-administered EQ-5D, Parkinson’s Disease
Sleep Scale (PDSS-2), and Beck Depression Inventories. Branded and generic ropinirole treatment achieved similar scores on
all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, 𝑃 = 0.505). Based on
patient diaries, the lengths of “good time periods” were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp.,
𝑃 = 0.670). However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus. 9.5
hours, 𝑃 < 0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus. 1.0 hours, 𝑃 < 0.05) than the branded ropinirole
did. Except for gastrointestinal problems, nonmotor symptomswere similarly controlled. Patients did not prefer either formulation.
Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration
can achieve similar control on most symptoms of PD.
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease hav-
ing major burdens on both the families and the healthcare
system. Although most symptoms of PD have an excellent
response to dopamine replacement therapies (e.g., levodopa
and dopamine agonists, DA) in the early phase, the response
to medication may become progressively inconsistent as the
disease progresses. As the therapeutic window becomes nar-
rower, long-term complication of dopaminergic treatment
develops. The pharmacological management of wearing off,
fluctuations, and dyskineasias (both chorea and dystonia)
may be challenging. Therefore, patients with advanced PD
usually require complex drug combinations, more frequent
dosing, and usually increased dosages [1, 2].
Although dopaminergic medications are not considered
as very expensive compared to other pharmacological agents,
the long treatment duration and the frequent need to
use complex combinations [1] makes the overall cost on
these drugs high. The economic crisis and aging society
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encourage social security providers to reduce healthcare-
related expenses, for example, by the application of generic
drugs as substitutes for branded agents [3].
Medicinal products are considered to be pharmaceuti-
cally equivalent if they contain the same amount of the same
active substance(s) in the same dosage forms that meet the
same or comparable standards. Pharmaceutical equivalence
does not necessarily imply bioequivalence as differences in
the excipients and/or the manufacturing process can lead to
faster or slower dissolution and/or absorption.
On the basis of European Medicines Agency (EMA) rec-
ommendations, two medicinal products containing the same
active substance are considered bioequivalent if they are
pharmaceutically equivalent or pharmaceutical alternatives
(medicinal products with same active substance but in dif-
ferent salts or esters, etc.) and their bioavailabilities (rate
and extent) after administration in the same molar dose lie
within acceptable predefined limits [4]. The current concept
is that pharmaceutical equivalence and bioequivalence are
used as a surrogate measure for therapeutic effect [5]. Similar
guidelines exist worldwide. For example, the Food and Drug
Administration (FDA) requires almost the same parameters
for licensing a generic drug [6].
Based on the assumption that bioequivalence equals ther-
apeutic equivalence, generic and branded drugs can be used
interchangeably. The regulatory limits applied in bioequiva-
lence studies require that the areas under the drug concen-
tration (AUC) versus time curves must be within 90% con-
fidence intervals and the maximum plasma concentrations
(𝐶max)must fall within 80–125% [4].This rule implies that the
difference theoretically could be as much as a 56% increase or
36%decrease in bioavailability when switching a patient from
one generic to another generic formulation [4, 7].
It is well known that blood levels of levodopa (and DA)
correlate with the appearance of both motor and nonmotor
symptoms PD [8] and consequently can impact quality of life
[9]. In particular in the advanced stage of PD, neither the too
low nor the too high plasma concentration of dopaminergic
medication is appropriate. The too low plasma levels could
induce or worsen OFF periods, whereas the high levels could
elicit or worsen dyskinesia [10]. Therefore, one could assume
that the demonstration of an 80–125% bioequivalence for a
generic drug compared to the branded medication might be
too wide and could interfere with the PD symptoms.
Based on this assumption and the previously described
correlation between the late dopaminergic side-effects and
plasma concentrations, one can argue that dopaminergic
drugs licensed for advanced PD should be considered as
narrow therapeutic index drugs (NTIDs), in which group
the acceptance interval for AUC is tightened by the cur-
rent regulations to 90.00–111.11% in bioequivalence studies
[11]. Although the current EMA regulations imply specific
rules for NTIDs [12], these regulations are not applied for
dopaminergic drugs. According to the revised guideline on
the investigation of bioequivalence of EMApublished in 2010,
“It is not possible to define a set of criteria to categorize drugs
as NTIDs and it must be decided case by case if an active
substance is an NTID based on clinical considerations [11].”
Further possible issues in the generic drug prescription
for advancedPDmight be raised.One possible concernmight
be that currently bioequivalencemeasurements for dopamin-
ergicmedications are not performedonPDpatients.Whereas
the development of a brandedmedication demands the estab-
lishment of pharmacokinetics, efficacy, safety, and tolerability
on both healthy and target patient population, the licensing
of a new generic drug requires only the demonstration of
bioequivalence with the branded counterpart, which is done
only in healthy subjects [13]. Therefore, the gastrointestinal
features of PD might also have an—uninvestigated—impact
on the efficacy of generic drugs. Whereas neither the current
nor the proposed [14] guideline of EMA on orally modified-
release agents demands so, the product-specific guidance on
ropinirole-hydrochloride of the Food and Drug Administra-
tion requires bioequivalence studies in both fasting and fed
conditions.
There are very few available reports from either patients
or physicians that address the question of generic drug-usage
in PD from clinical perspectives [13]. The majority of these
data compared the original levodopa formulations to generic
ones anddemonstrated that theminority of patients (31%) did
not tolerate generic formulations [13, 15].
Recently, a study compared the pharmaceutical quality
of seven generic levodopa/benserazide hydrochloride com-
bination products marketed in Germany with the original
product (Madopar) [16]. All generic products (100mg/25mg
formulations) were tested against Madopar 125 tablets. They
assessed the disintegration and dissolution, content, identity,
and amounts of impurities along with standard physical and
chemical laboratory. The authors state that each of the seven
generic products had one or two parameters outside the
specifications. Deviations for the active ingredients ranged
from +8.4% (benserazide) to −7.6% (levodopa), whereas
degradation products were measured in apparent excess
(+26.5%) in one capsule formulation [16]. However, disinte-
gration time and dissolution for levodopa and benserazide
hydrochloride at 30min were within specifications with
some outliers [16]. The authors concluded that deviations
for the active ingredients may go unnoticed by a new user
of the generic product but may entail clinical consequences
when switching from original to generic during a long-term
therapy. Based on their opinion, degradation products may
also pose a safety concern [16].
Even less data is available on the generic formulations
of DAs. Because modified-release (usually extended-release)
formulations of various DAs are available on the market,
another issue might be raised concerning the length of clin-
ical action. Whereas branded extended-release dopamine-
agonists are claimed to have beneficial effects lasting for
24 hours, EMA and other regulators do not require any
clinical evaluation of duration of action before licensing
new extended-release generic drug formulations. Instead of
clinical studies, the performance ofmuch cheaper dissolution
tests is required [14].
The aim of the present study was to compare the clinical
efficacy of the branded extended-release ropinirole (Requip
modutab, GlaxoSmithKline) with an also extended-release
generic comparator (Ralnea, Krka, Slovenia). We assumed
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that any significant differences between these two formula-
tions could produce altered severity of either motor or non-
motor symptoms of PD.
2. Methods
2.1. Patients. Twenty-two Parkinson’s disease (PD) patients
with fluctuation were enrolled to our study (age: 69.3 ± 10.9
years, sex: 17 males, disease duration: 6.5±2.9 years, and type
of PD: 17 rigid-akinetic, 5 mixed). All of them had advanced
PD with long-term dopaminergic side-effects (wearing off
andfluctuation) and received levodopa (423.8±249.3mg) and
ropinirole (15.0 ± 5.6mg) combination therapy. Each patient
took extended-release (retard) formulation of ropinirole
once-a-day, in the morning.
Inclusion criteria for participation were the following:
(i) fulfillment of the UK Brain Bank clinical diagnostic
criteria for PD [17],
(ii) receiving stable (≥8mg/day) dosage of extended-
release ropinirole >3 months,
(iii) stable symptoms of PD before enrollment,
(iv) signed written consent according to the approval of
Regional Ethical Board.
Exclusion criteria were the following:
(i) presence of other disorders capable of producing
tremor (e.g., hyperthyroidism),
(ii) suspicion of any Parkinson Plus syndromes or sec-
ondary parkinsonism,
(iii) abnormal brain MRI (e.g., hydrocephalus, brainstem
atrophy, and metal deposition),
(iv) implanted deep brain stimulator,
(v) levodopa/carbidopa intestinal gel infusion therapy,
(vi) history of drug abuse,
(vii) presence of any contraindications for ropinirole
administration,
(viii) presence or history of impulsive control disorder,
(ix) suspicion of psychogenic symptoms,
(x) presence of any disorders capable of interfering with
the study (e.g., severe heart failure, severe arthritis,
severe liver problems, or dementia).
Patients were examined at Department of Neurol-
ogy, University of Pe´cs (Pe´cs, Hungary) and Kaposi Mo´r
County Hospital (Kaposva´r, Hungary). The study protocol
was approved by the Regional Ethical Board (4230.316-
2470/KK15/2011). Our examination was an investigator initi-
ated and noncommercial study. Requip modutab and Ralnea
medication were obtained from GSK and Krka pharmaceu-
tical companies, respectively. None of the manufacturers had
any influence on the present study.
2.2. Methods. Our a priori hypothesis was that the generic
ropinirole has noninferiority compared to the branded one.
The study had a rater-blinded and crossover design lasting for
3months. At enrollment and 1month later (Visits 1 and 2), the
patients received stable dosage of branded ropinirole (Requip
modutab). After completing the tests of Visit 2, the patients
switched to same dosage of generic ropinirole; therefore, we
evaluated the clinical effects of Ralnea at Visits 3 and 4. Except
for switching from Requip to Ralnea, the patients received
unchanged medication and dosing throughout the study.
Before enrollment, neuropsychological tests (Mini-Men-
tal Status Examination, Mattis Dementia Rating Scale) were
applied to exclude demented patients [18]. We used the Hun-
garian validated cut-off score of 125 to exclude patients [18].
At each visit, the motor symptoms (Unified Parkinson’s
Disease Rating Scale part 3, UPDRS-3; Fahn-Tolosa-Marin
Tremor Rating Scale part A, FTMTRS-A, and modified
Hoehn-Yahr Stage, HYS) were tested at the same part of the
day. These tests were scheduled 1.5 hours after the intake of
last levodopa dose. We videotaped the application of these
motor tests according to our video protocol [19]. After the
accomplishment of the study, a rater specialized inmovement
disorders and blinded to the treatment (EB) reevaluated these
digitalized and anonymous video recordings. The scores of
these motor tests (except for rigidity subscore of UPDRS-
3) were obtained during this blinded reevaluation [19]. We
considered the severity of motor symptoms measured by
UPDRS-3 as the primary endpoint of the study, whereas
FTMTRA-A and HYS served as secondary endpoints.
A trained Parkinson nurse obtained the rest of UPDRS
(parts 1, 2, and 4), FTMTRS (parts B and C), Nonmotor
Symptom Assessment Scale (NMSS), activity of daily living
(Schwab and England, ADL), a structured questionnaire
on ropinirole side-effects, and Montgomery Asberg Depres-
sion Rating Scale (MADRS). Besides, the patients also self-
administered the EQ-5D quality of life instrument [20],
Parkinson’sDisease Sleep Scale (PDSS-2), Epworth Sleepiness
Scale (ESS), and Beck Depression Inventory (BDI).
We asked our patients to keep patient diaries at least 2
days before each visit to assess ON-time without dyskinesia,
ON-time with slight dyskinesia, ON-time with severe dyski-
nesia, OFF-time, and daytime sleeping time [19]. “Good time”
was defined as the sum of ON periods without dyskinesia
and slight, nondisturbing dyskinesia [21–23]. During the last
(fourth) visit we also obtained a structured inventory on the
comparison of branded and generic ropinirole.
2.3. Statistical Methods. Because most of the variables did
not follow the normal distribution, nonparametric tests were
applied. Kruskal-Wallis test was assessed to evaluate any dif-
ferences between Visits 1–4 except for HYS where Chi-square
test was calculated by using SPSS Software (IBM Inc, version
19, IL). Wilcoxon’s signed rank test was used during the
comparison of two visits for continuous variables, whereas
McNemar test for dichotomous variables and Chi-square for




Twenty-one patients completed the study; only their data
were used for further analyses. One patient withdrew from
the study because he moved to another city and consequently
became unable to carry on with the protocol.
The result of Mini-Mental Status Examination was 26.6 ±
2.6 points, whereas the average score on Mattis Dementia
Rating Scale [18] was 133.0 ± 7.8 points.
Before further analyses, we compared the results of Visit
1 with Visit 2. Because none of the examined variables
changed significantly between Visits 1-2, we assumed that our
patients did not experience any changes (either worsening or
improvement) during the Requip modutab phase. Similarly
we did not identify any changes during the stable Ralnea
phase (between Visits 3-4).
3.1. Motor Symptoms. As far as the motor symptoms were
concerned, we did not observe any differences between each
visit (UPDRS-3, FTMTRS-A, HYS, 𝑃 > 0.05, Table 1).
3.2. Patient Diary. The analysis of the patient diary revealed
that the length of ON periods without dyskinesia decreased
(worsened) from 9.5 hours to 6.5 hours after switching from
branded to generic ropinirole (𝑃 = 0.01, Table 1). Simul-
taneously, the length of ON periods with slight dyskinesia
increased from 1.0 to 3.5 hours (𝑃 < 0.05). Consequently,
the length of “good time periods” remained unchanged
between the branded and generic ropinirole treatment phase
(10.5 versus 10.0 hours, 𝑃 > 0.05, Table 1). Similarly, the
lengths of OFF periods, ON periods with severe dyskinesia,
daytime sleep, and nighttime sleep periods did not change
significantly (Table 1).
3.3. Other Tests. Among the nonmotor tests (PDSS-2, ESS,
NMSS, EQ-5D, ADL, MADRS, and BDI) only the gastroin-
testinal section of NMSS showed worsening during generic
ropinirole treatment (from 4.0 to 8.0 points, 𝑃 < 0.05,
Table 1). However, the side-effect profile of both medications
was comparable on the structured ropinirole side-effects
questionnaire (Table 2). The analysis of the after completion
feedback forms revealed that similar number of patients
requested Requip and Ralnea medication after completion of
the study (12 versus 9, resp., 𝑃 = 0.513, Table 3). Six months
later 8 patients were on branded, whereas 13 subjects were on
generic formulation (𝑃 = 0.275).
4. Discussion
To our knowledge, our study is the first direct comparison
of the branded and a generic extended-release ropinirole in
the treatment of advanced PD. Although, our results demon-
strated that both generic ropinirole and branded ropinirole
usage achieved similar motor-symptom control measured by
UPDRS-3 and met the criteria for the primary endpoint,
some differences could also be revealed. The usage of generic
formulation was associated with higher rate of gastrointesti-
nal symptoms measured by NMSS, which was inconsistent
with the results of the ropinirole side-effects questionnaire.
Besides, the length of ON periods without dyskinesia was 3.0
hours shorter and the length of ON periods with slight and
nondisturbing dyskinesia was almost 2.5 hours longer during
the generic medication usage. Despite the above mentioned
differences in gastrointestinal symptoms and patient diary
periods, the patients did not prefer either formulation after
completing the study protocol.Thismight be due the fact that
the time with “good periods” [21–23] remained comparable
between the Requip and Ralnea treatments (10.5 versus 10.0
hours, resp.) and the severity of motor and most nonmotor
symptoms was also similar.
The clinical significance of the increased ON time
with slight dyskinesia during the administration of generic
ropinirole remains unknown. We might assume that this
phenomenon is probably due to slightly increased level of
serum ropinirole during the periods of dyskinesia. Because
the results of quality of life scales did not differ between the
branded and generic ropinirole administration, its clinical
relevance on the patients’ everyday life might be minimal.
One of our key findings was that the generic formulation
(Ralnea) achieved similar control on the motor and nonmo-
tor symptoms of PD and both formulations had similar safety
and side-effect profile with the exception of gastrointestinal
problems. Although the NMSS score on gastrointestinal
problems significantly increased during the generic ropini-
role treatment phase, the patient reported side-effect profile
was similar in both generic and branded ropinirole treatment
phases.
This basically positive outcome may also be verified by
the clinical practice of the authors, because we have not
observed any serious clinical issues with this generic ropini-
role formulation since their introduction to the Hungarian
market in 2011. Despite similar number of patients choosing
the branded and the generic formulations of ropinirole
therapy immediately after completion of the study, 6 months
later somewhat more patients were on generic formulation
medication. In the background of this tendency, the increased
financial burden of patients may be suspected. As the generic
ropinirole formulations spread into the Hungarian market,
the reimbursement of the branded formulation was low-
ered by the government-based healthcare system. Therefore
the end-user price of branded ropinirole became increased
compared to its comparators. In our opinion, the increased
patients’ costs might have been the main reason why increas-
ingly more patients chose the generic ropinirole treatment.
Although studies of generic versus branded products
are very difficult to perform across a large population of
patients, the authors are aware of the major limitations of the
study: because our study was not a randomized and double-
blind examination, the patients’ preference and beliefs might
have biased the results. Theoretically we could have applied
overcapsulation to ensure double-blind evaluation, but we
were unable to organize such study without appropriate
funding. Therefore, we applied a blinded-rater approach and
planned four visits (2 with branded and 2 with generic drug
usage) to minimize possible biases.
Another limitation of the study is the lack of pharmacok-
inetic data. Because our study was a nonsponsored and
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Table 1: Results of tests measuring various motor and nonmotor symptoms.









UPDRS part I 2.0 2.0 4.0 3.0 2.5 5.0 0.566
UPDRS part II 15.0 12.0 17.0 15.0 9.5 19.0 0.928
UPDRS part III 27.0 20.5 31.0 28.0 23.0 33.5 0.505
UPDRS part IV 8.0 5.0 10.0 7.0 5.0 9.5 0.857
UPDRS total score 52.0 40.5 59.5 55.0 42.5 66.5 0.776
HYS 2.0 2.0 2.5 2.0 2.0 2.8 0.785
Tremor
FTMTRS part A 5.0 3.5 9.0 5.0 4.0 7.0 0.919
FTMTRS part B 10.0 9.0 10.5 12.0 9.5 13.0 0.502
FTMTRS part C 10.0 8.0 10.5 9.0 6.0 11.0 0.810
FTMTRS total score 25.0 21.0 29.0 25.0 22.0 28.5 0.918
Patient diary
ON time without
dyskinesia (hours) 9.5 7.5 12.0 6.5 3.5 8.4 0.010
ON time with slight
dyskinesia (hours) 1.0 0.0 2.5 3.5 0.5 4.5 0.041
“Good” time 10.5 7.5 13.5 10.0 8.0 13.0 0.670
ON time with severe
dyskinesia (hours) 0.5 0.0 1.0 0.5 0.0 1.5 0.612
OFF time (hours) 4.5 3.5 7.5 4.5 1.5 11.5 0.778
Daytime sleeping hours 0.5 0.0 1.5 0.5 0.0 1.0 0.828
Nighttime sleeping






2.0 0.0 6.0 3.0 0.0 7.0 0.633
NMS section II (sleep
subscore) 17.0 11.0 26.0 20.0 15.0 26.0 0.993
NMS section III (mood




0.0 0.0 8.0 0.0 0.0 4.0 0.974
NMS section V








13.0 9.0 19.5 14.0 9.0 20.5 0.878
NMS section VIII
(sexual subscore) 2.0 0.0 10.0 2.0 0.0 5.0 0.197
NMS section IX
(miscellaneous subscore) 1.0 0.0 9.0 1.0 0.0 7.0 0.251
NMS total score 85.0 47.0 103.5 90.0 59.5 115.5 0.939
Sleep and
sleepiness
PDSS-2 motor subscore 3.0 0.0 7.0 2.0 1.0 7.0 0.397
PDSS-2 Parkinsonian
symptoms subscore 4.0 2.0 5.5 3.0 1.0 5.5 0.657
PDSS-2 disturbed sleep
subscore 6.0 3.5 9.5 7.0 3.5 11.0 0.334
PDSS-2 total score 12.0 7.5 18.5 10.0 8.0 23.0 0.224
ESS Total 7.0 6.0 12.0 7.0 5.5 12.0 0.567
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Table 1: Continued.








Depression BDI total score 10.0 5.5 15.5 9.0 5.0 14.0 0.858
MADRS total score 10.0 5.5 15.0 11.0 7.5 15.5 0.623
QoL
EQ-5D 0.8 0.7 0.9 0.8 0.7 0.9 0.895
EQ-VAS 70.0 54.0 80.0 63.0 50.0 76.0 0.625
ADL (Schwab-England) 80.0 75.0 90.0 80.0 70.0 90.0 0.965
Clinical global




4.0 4.0 4.0 4.0 4.0 5.0 0.199
ADL = activities of daily living (Schwab and England Scale). BDI = Beck Depression Inventory; ESS = Epworth Sleepiness Scale; EQ-5D = the EuroQol
instrument for detecting health outcome; EQ-VAS = visual analogue scale included in EQ-5D; HYS = Hoehn-Yahr Stage; FTMTRS = Fahn-Tolosa-Marin
Tremor Rating Scale; MADRS =Montgomery Asberg Depression Rating Scale; NMSS = Nonmotor SymptomAssessment Scale; PDSS-2 = Parkinson’s Disease
Sleep Scale 2nd version; UPDRS = Unified Parkinson’s Disease Rating Scale. For calculating significance Kruskal-Wallis test was applied except for HYS and
Clinical Global Impression scales where Chi-square test was used (because of being an ordinal variable).
Table 2: Side-effect profile.
Requip (present/absent) Ralnea (present/absent) McNemar test (𝑃 value)
Orthostatic hypotension 9/12 9/12 1.000
Daytime sleepiness 18/3 19/2 1.000
Dizziness 8/13 8/13 1.000
Confusion 0/21 2/19 0.500
Dyskinesia 14/7 17/4 0.219
Hallucinations or pseudohallucinations 4/17 3/18 1.000
Sexual disturbances 1/20 2/19 1.000
Abdominal pain/discomfort 2/19 7/14 0.125
Nausea 1/20 3/18 0.500
Constipation 7/14 6/15 1.000
Oedema 13/8 10/11 0.250
Impulse control disorder 0/21 0/21 1.000
Table 3: Results of the poststudy patient questionnaire.
Question Responses (Requip/Ralnea/Similar) Chi-square test
Overall which formulation had better efficacy? 9/4/8 0.368
Which formulation had better control on motor symptoms? 10/3/8 0.156
Which formulation had better control on nighttime symptoms? 5/6/10 0.368
Which formulation had better control on nonmotor symptoms? 8/0/13 0.275
Which formulation would you like to receive after the completion of the study? 12/9 0.513
investigator-initiated examination, we did not have any
opportunity to study the pharmacokinetics of the branded
and generic ropinirole.
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